Atrial fibrillation drugs get committee review
Executive Summary
FDA's Cardio-Renal Drugs Advisory Committee will review two new chemical entities for acute conversion of atrial fibrillation Dec. 11-12, Cardiome/Astellas' vernakalant and Solvay's Pulzium (tedisamil), according to Cardiome. The meeting date comes after vernakalant's user fee date, necessitating a three-month user fee extension to Jan. 19. Executives at Cardiome indicated the decision was likely due to the agency's decision to put Solvay's competing product - submitted months after the NDA for vernakalant had been filed - under an advisory committee review. Cardiome submitted its NDA for an intravenous version of vernakalant in December, while Solvay announced its NDA filing for an IV Pulzium formulation in April...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.